You are here

  • Home
  • Archive
  • Volume 9, Issue 3
  • Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer

 

Online download statistics by month:

Online download statistics by month: March 2021 to August 2025

AbstractFullPdf
Mar 202110321032170
Apr 202125725778
May 202124924986
Jun 202117117137
Jul 202114614627
Aug 202116116025
Sep 202116216240
Oct 202114114149
Nov 202113513427
Dec 202111111112
Jan 202211912332
Feb 202210210235
Mar 202212512749
Apr 202213113325
May 2022819028
Jun 202216716735
Jul 202212112324
Aug 202213513936
Sep 202216516533
Oct 202210210232
Nov 202210911147
Dec 2022777711
Jan 202311611733
Feb 202313713720
Mar 202319719840
Apr 2023676715
May 2023767623
Jun 2023959515
Jul 2023747446
Aug 2023606019
Sep 2023545522
Oct 2023535319
Nov 202311711818
Dec 2023727333
Jan 2024363735
Feb 2024939337
Mar 202411711798
Apr 202410210236
May 202415916338
Jun 2024686831
Jul 202412012135
Aug 2024777416
Sep 202450350391
Oct 2024898937
Nov 2024979841
Dec 202411011140
Jan 2025969843
Feb 202517717864
Mar 2025868625
Apr 202511511548
May 202512512851
Jun 2025626224
Jul 2025110
Aug 2025110
Total735173902031